CTOs on the Move

BioPlus Specialty Pharmacy

www.bioplusrx.com

 
BioPlus Specialty Pharmacy is a leading independent, national specialty pharmacy with 28 years of innovative excellence and the first and only specialty pharmacy to offer a two-hour turnaround from referral to patient acceptance. BioPlus earned a #1 patient satisfaction ranking in both oncology and hepatitis C in Zitter`s Specialty Pharmacy Patient Satisfaction Survey. Our RxExpress program moves each prescription through our system in the most streamline way. From the 2-Hour Patient Acceptance Guarantee at the beginning to the 2-Day Ready 2 Ship at the end, along with free overnight shipping, physicians and patients can trust BioPlus to provide effective service ...
  • Number of Employees: 250-1000
  • Annual Revenue: $10-50 Million
  • www.bioplusrx.com
  • 376 Northlake Boulevard
    Altamonte Springs, FL USA 32701
  • Phone: 407.830.8820

Executives

Name Title Contact Details

Similar Companies

R&S Northeast

R&S Northeast, LLC has operated as a national pharmaceutical wholesaler since 1973.

CDx Diagnostics

The developer of advanced diagnostic tests that empower physicians to preempt cancer, including WATS3D, for increased detection of Barrett`s esophagus and dysplasia.

DrugSense

DrugSense is a Irvine, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Merz

Merz Pharmaceuticals is an innovative pharmaceutical company specializing in the research and marketing of drugs for the treatment of

RedHill Biopharma

RedHill Biopharma, established in 2009, is a publicly traded (NASDAQ: RDHL) (Tel-Aviv Stock Exchange: RDHL) specialty biopharmaceutical company, headquartered in Israel, primarily focused on the development and commercialization of late clinical-stage, proprietary, orally-administered, small molecule drugs for the treatment of gastrointestinal and inflammatory diseases, including cancer. RedHill’s pipeline includes several drug candidates in advanced clinical development stages addressing clear medical needs and aiming to relieve suffering and save lives. RedHill’s drugs are largely de-risked and are potentially of lower cost and faster to market than new chemical entities under development. RedHill’s products are based on several technology platforms and address several disease targets, thus providing for risk diversification. RedHill’s U.S. commercial operations, headquartered in Raleigh, NC, include a gastrointestinal-focused sales force of approximately 40 sales representatives promoting two speciality gastrointestinal products in select U.S. territories. RedHill’s experienced management team, board of directors and advisory board, based in Israel, the US, Canada and Europe, comes with a successful track record of bringing patented drugs to the market, as well as extensive managerial, financial, and transactional expertise. '